Prospective study of side effects associated with the use of silver sulfadiazine in severely burned patients.
We report the results of a prospective study of 45 burn patients in whom serum and urine levels of cream constituents (sulfadiazine and propylene glycol) were determined and correlated with clinical parameters and the presence of an immune response to sulfadiazine. Propylene glycol, measured by gas chromatography, was found in the serum of 53% of study patients. Sulfa, determined by spectroscopy, was found in the serum of all patients, with values as high as 9.1 mg/dl within 24 hours of topical application. Ninety percent of tested patients had circulating sulfadiazine antibodies, predominantly IgG. Fourteen patients died, 11 of whom had interpretable renal biopsies. Five of these biopsies showed positive immunofluorescent linear or granular staining for IgG, IgM, IgA, or C'3; none of these 5 patients had clinical evidence for the nephrotic syndrome. The association between antisulfadiazine antibodies, circulating immune complexes, immunoglobulin disposition on glomerular basement membranes, and topical application of silver sulfadiazine provides evidence for sulfadiazine sensitization in patients with severe burns.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D000936:Antigen-Antibody Complex / Q000032:analysis; D002056:Burns / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003176:Complement C3 / Q000032:analysis; D003378:Counterimmunoelectrophoresis; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007223:Infant; D007668:Kidney / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D009994:Osmolar Concentration; D019946:Propylene Glycol; D011409:Propylene Glycols / Q000276:immunology / Q000378:metabolism; D011446:Prospective Studies; D012837:Silver Sulfadiazine / Q000009:adverse effects* / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use; D013411:Sulfadiazine / Q000009:adverse effects*
D000906:Antibodies; D000936:Antigen-Antibody Complex; D003176:Complement C3; D007136:Immunoglobulins; D011409:Propylene Glycols; D013411:Sulfadiazine; D019946:Propylene Glycol; D012837:Silver Sulfadiazine